Esperion Therapeutics (ESPR) Active as Merck Reports IMPROVE-IT Met Primary Endpoint
Tweet Send to a Friend
Esperion Therapeutics (NASDAQ: ESPR) was active Monday ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
